ARGX · US market

ARGENX

Compare this company’s P/E and P/S using trailing results and the latest quarter. Ratios are calculated here from market capitalisation, signed ordinary or common-shareholder earnings and revenue.

Market cap US$57.92bnFinancials dated 31 March 2026Price dated 1 October 2026

Core valuation

Trailing P/E38.91×

Latest-quarter run-rate P/E39.56×

Trailing P/S12.18×

Latest-quarter run-rate P/S11.03×

Calculation inputs

Trailing earnings: US$1.49bn
Latest-quarter run-rate earnings: US$1.46bn
Latest fiscal-year earnings: US$1.29bn
Trailing revenue: US$4.75bn
Latest-quarter run-rate revenue: US$5.25bn
Latest fiscal-year revenue: US$4.25bn

Featured ETF and mutual-fund exposure

These public funds report this company in their latest disclosed holdings.

EWK · iShares MSCI Belgium ETF17.32% weight · Holdings dated 21 August 2026
BBH · VanEck Biotech ETF4.97% weight · Holdings dated 30 June 2026
ARTMX · Artisan Mid Cap Fund Investor Class4.93% weight · Holdings dated 30 June 2026
IBRN · iShares Neuroscience and Healthcare ETF4.33% weight · Holdings dated 21 August 2026
GDOC · Goldman Sachs Future Health Care Equity ETF4.07% weight · Holdings dated 31 May 2026
IBB · iShares Biotechnology ETF3.68% weight · Holdings dated 19 August 2026
APSDX · NYLI Fiera SMID Growth Class R63.52% weight · Holdings dated 30 April 2026Holdings available · disclosure too old for reliabilityHoldings dated 30 April 2026 are 162 days old, beyond this source’s 155-day reliability limit. Ratios remain available as dated research; calculations are unchanged and are not labelled reliable.
FBT · First Trust NYSE Arca Biotechnology Index Fund3.13% weight · Holdings dated 30 June 2026
KLCAX · Federated Hermes Kaufmann Large Cap Fund Class A3.04% weight · Holdings dated 30 April 2026Holdings available · disclosure too old for reliabilityHoldings dated 30 April 2026 are 162 days old, beyond this source’s 155-day reliability limit. Ratios remain available as dated research; calculations are unchanged and are not labelled reliable.
FMED · Fidelity Disruptive Medicine ETF2.78% weight · Holdings dated 31 May 2026

Sources and limitations

Financial inputs are attributed to SEC EDGAR. Market cap is calculated locally where auditable price and share inputs are available. Missing data stays missing; losses are retained as signed values and produce a numeric signed P/E.

Open financial source

Financials as of 31 March 2026. Informational research, not investment advice.